206 related articles for article (PubMed ID: 37141764)
1. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
Surti TS; Ranganathan M; Johannesen JK; Gueorguieva R; Deaso E; Kenney JG; Krystal JH; D'Souza DC
Schizophr Res; 2023 Jun; 256():36-43. PubMed ID: 37141764
[TBL] [Abstract][Full Text] [Related]
2. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
D'Souza DC; Carson RE; Driesen N; Johannesen J; Ranganathan M; Krystal JH;
Biol Psychiatry; 2018 Sep; 84(6):413-421. PubMed ID: 29499855
[TBL] [Abstract][Full Text] [Related]
3. Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition.
Möhler H; Boison D; Singer P; Feldon J; Pauly-Evers M; Yee BK
Biochem Pharmacol; 2011 May; 81(9):1065-77. PubMed ID: 21333635
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
Fleischhacker WW; Podhorna J; Gröschl M; Hake S; Zhao Y; Huang S; Keefe RSE; Desch M; Brenner R; Walling DP; Mantero-Atienza E; Nakagome K; Pollentier S
Lancet Psychiatry; 2021 Mar; 8(3):191-201. PubMed ID: 33610228
[TBL] [Abstract][Full Text] [Related]
5. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Singer P; Dubroqua S; Yee BK
Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
[TBL] [Abstract][Full Text] [Related]
8. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.
Ranganathan M; DeMartinis N; Huguenel B; Gaudreault F; Bednar MM; Shaffer CL; Gupta S; Cahill J; Sherif MA; Mancuso J; Zumpano L; D'Souza DC
Mol Psychiatry; 2017 Nov; 22(11):1633-1640. PubMed ID: 28242871
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial.
Harvey PD; Bowie CR; McDonald S; Podhorna J
Clin Drug Investig; 2020 Apr; 40(4):377-385. PubMed ID: 32036587
[TBL] [Abstract][Full Text] [Related]
12. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia.
Rosenbrock H; Dorner-Ciossek C; Giovannini R; Schmid B; Schuelert N
J Pharmacol Exp Ther; 2022 Aug; 382(2):223-232. PubMed ID: 35661632
[No Abstract] [Full Text] [Related]
15. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
16. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
17. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
Dunayevich E; Buchanan RW; Chen CY; Yang J; Nilsen J; Dietrich JM; Sun H; Marder S
Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188
[TBL] [Abstract][Full Text] [Related]
19. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.
Rosenbrock H; Desch M; Wunderlich G
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1557-1566. PubMed ID: 36971864
[TBL] [Abstract][Full Text] [Related]
20. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
